Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

Bernstein analyst Florent Cespedes maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK560.00. The company’s shares closed last Friday at ...

Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a ...

Novo Nordisk A/S (NVO) investors who had anticipated that the stock could continue outperforming the market were likely disappointed. Accordingly, NVO has underperformed the S&P 500 (SPX ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel hemophilia treatment concizumab. Meanwhile, PTC Therapeutics' troubled ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks discussed by Jim Cramer during the latest lightning round. On Tuesday, Jim Cramer ...

(Image Credits: Pixabay) Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...

Citigroup has promoted three senior healthcare investment bankers - Sumit Khedekar, Nishant Jadav and Michael Guarino - in ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...